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This year-end issue typically serves as an opportunity to reflect on the year’s notable
events and accomplishments in TB control and elimination. It’s a time to celebrate the
hard work of all in the TB community and to look ahead to opportunities for the next
year.
In a number of respects, this has been a challenging year. We started 2013 with news
of a shortage of isoniazid, one of the first-line drugs used to fight TB. The nation also
experienced shortages of Tubersol and Aplisol, the only two tuberculin products
commercially available for use in the diagnosis of infection with Mycobacterium
tuberculosis.
In March, CDC’s grantees received a letter announcing a series of spending cuts that
significantly reduced federal resources. These cuts necessitated some difficult decisions
about staffing and program activities.
In August, DTBE’s Director, Dr. Castro, left DTBE to serve in a temporary capacity as
Acting Director of the Division of HIV/AIDS Prevention when its director, Jonathan
Mermin, was selected as the new Director of NCHHSTP. I have been honored to serve
as Acting Director of DBTE in Dr. Castro’s absence. In the same month, DTBE staff
packed up files, papers, books, and documents, and moved (to the building next door)
as part of series of moves to consolidate CDC staff, as much as possible, and to use
government-owned rather than leased property.
In October, most of the staff members of our Division were furloughed for 17 days.
During this time, DTBE could only address urgent issues, and many important activities
experienced interruptions and delays.
However, there were also positive events and substantial accomplishments this past
year. We welcomed a new Regional Training and Medical Consultation Center
(RTMCC), the Mayo Center for Tuberculosis, located in Rochester, Minnesota. With the
addition of the Mayo TB Center, the RTMCCs saw a reconfiguration of their coverage
areas. We appreciate the efforts and cooperation of all involved in making this
transition.
In March, CDC’s World TB Day observance was held. Dr. Kenneth Castro, Director,
DTBE, led the proceedings. Dr. Terrence Lo, EIS officer in DTBE, gave the TB trends





            
          
             
               
             
             
             
                
                 
           
 
              
           
             
        
            
                   
          
 
              
           
           
            
          
              
 
            
             
              
              
             
         
 
               
            
            
              
           
 
                
              
           
 
              
             
             
Georgia Department of Public Health, gave an inspiring and notable keynote address.
Dr. Wanda Walton, Chief, Communications, Education, and Behavioral Studies Branch
(CEBSB), DTBE, reported on DBTE’s TB Personal Story project. In this initiative, TB
and LTBI patients describe their TB experience, in print or on camera; these stories are
then posted online. Three patients from Atlanta, Georgia, told their stories on camera,
and Dr. Walton shared their stories at the observance. DTBE is seeking additional
participants for this project. If you know of a person who successfully completed
treatment for TB or LTBI, with help from the local TB program, whose TB story is
compelling, and who is willing to share the story in person or in print, please let us
know. Please contact Nicole Richardson-Smith or Ann Lanner to learn more.
On October 25, CDC released new guidelines on the use of bedaquiline fumarate, a
new drug available to treat multidrug-resistant tuberculosis (MDR TB) — Provisional
CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for
the Treatment of Multidrug-Resistant Tuberculosis. Bedaquiline, which received
accelerated approval from the Food and Drug Administration (FDA) in December 2012,
is the first new type of TB drug to be approved in over 40 years to treat this deadly
disease. Please see a report on it in this issue.
In July, Dr. Castro took part in a successful Healthy People 2020 Progress Review
webinar, featuring the Immunization and Infectious Diseases and Global Health topic
areas. The webinar examined the burden of infectious diseases nationally and
internationally, with a special emphasis on TB. Participants also learned about one
community-based organization’s work on TB prevention and treatment in the U.S.­
Mexico border region. You can read a summary of the event in this issue.
This fall, DTBE released its annual surveillance report, Reported Tuberculosis in the
United States, 2012, as well as the accompanying slide set. The report presents
summary data for TB cases verified and counted in 2012. This edition contains a
number of new tables, including genotyping data. In 2012, the reported number of TB
cases (9,945) and case rate (3.2 cases per 100,000) both decreased; these represent
declines of 5.4% and 6.1%, respectively, compared to 2011.
In July, the FDA gave authorization for the marketing of the Xpert MTB/RIF, the first
FDA-reviewed test that, in less than 2 hours, can simultaneously detect M. tuberculosis-
complex and determine if the bacteria contain genetic mutations that indicate resistance
to rifampin, an important antibiotic for the treatment of TB. In October, CDC published
an MMWR report providing guidance on use of the Xpert assay.
On a lighter note, staff of DTBE’s CEBSB had fun this summer and fall with their award-
winning TB educational product, Edgar Allan Crow. He/it won first prize at the Atlanta
Botanical Garden’s event, Scarecrows in the Garden. Read about it here.
As for 2014, we already know the year ahead will bring significant change. On
December 16, Dr. Castro announced his decision to vacate the position of Director,





                
              
                
           
            
          
             
    
 
                   
              
               
              





     
        
          
            
          
the Commissioned Corps near the end of FY 2014. He indicated that this was a very
difficult decision because of his passion for our shared mission and the great friends
and colleagues that he had enjoyed working with in DTBE over the past 20 years. His
tremendous achievements and impact on TB control and elimination efforts were
recently recognized when he was selected to receive the International Union Against
Tuberculosis and Lung Disease North American Region Lifetime Achievement Award.
The announcement for the recruitment of a new permanent Director, DTBE, will be
made in early 2014.
As the year draws to a close, I want to thank all of you for your hard work, resilience,
and commitment to the important mission of TB control and elimination. It’s a privilege
to work with such outstanding staff and partners, here and around the globe. Have a
peaceful and safe time with family and friends, and safe travels wherever your plans
take you this season.
Philip LoBue, MD, FACP, FCCP
Acting Director
Division of Tuberculosis Elimination
National Center for HIV/AIDS, Viral Hepatitis,
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Note: The use of trade names in this publication is for identification purposes only and does not imply
endorsement by the Centers for Disease Control and Prevention (CDC), the Public Health Service, or the
Department of Health and Human Services. The findings and conclusions in the articles published in TB
Notes are those of the authors and do not necessarily represent the official position of the Centers for
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Never having met a 
stranger, this man 
fills a room with his 
smile, infectious 
laugh, and loud, but 
reverent, “Can I 
hear an Amen?” 
when he, or 
someone else, 
provides an insight 
or statement about TB control activities and 
those whom we seek to serve in our TB public 
health positions. Even as his imposing physical 
presence draws your attention to him, it is his 
personal magnetism, his unparalleled ability to 
listen and really hear, that captivates and charms 
you. 
Dr. Charles E. Wallace recently retired from his 
position as Manager of the Tuberculosis Services 
Branch within the Texas Department of State 
Health Services, a position he held since 2007. 
His departure is a huge loss to the TB Branch, as 
his understanding of TB control has been learned 
over years of experience in the Department — 
first as a Public Health Technician in the City of 
Houston’s Health Department, and since 1985, in 
increasingly important and responsible positions 
in the Tuberculosis Control Division and the 
Infectious Disease Intervention and Control 
Branch within the Texas Department of State 
Health Services. 
Charles earned his master’s degree in public 
health in Maternal and Child Health, with a 
concentration in public administration, from the 
University of Pittsburgh, and his Doctorate of 
Philosophy in Education, with a specialty in 
human resource development and organizational 
behavior. Despite his impressive educational 
credentials, it was Charles’ real understanding of 
those within our communities who are minorities, 
impoverished, and suffering from disease, that 
contributed to his success. His knowledge of 
individuals, and the organizations designed to 
serve these individuals, facilitated his 
effectiveness and his ability to “be real” to those 
he served. 
We all know of his work in TB control in the state 
of Texas and at the national level, but few of us 
know of his early interest in, and contributions to, 
maternal and child health, sickle cell anemia, and 
minority health programs. Dr. Wallace’s 
commitment to those in our society who have 
fewer resources and who suffer from huge health 
disparities has been a pattern since the early 
1970s when he was the Executive Director of the 
Bexar County Anemia Association. There, he 
took special pride in the work he accomplished in 
directing the Southwest Sickle Cell Disease 
Education and Screening Clinic. 
Following these early experiences, Dr. Wallace 
served as the Community Health Director for the 
Albert Schweitzer Hospital in Haiti, where he 
organized, developed, and directed preventive 
health care services for 120,000 residents. Here 
is where he was first introduced to communicable 
disease control and surveillance, and where he 
developed an appreciation of the 
interconnectedness of global and domestic 
diseases, which ignited a spark and passion that 
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TB Notes is a quarterly publication of the Division
of TB Elimination (DTBE) of the National Center
for HIV/AIDS, Viral Hepatitis, STD, and TB
Prevention (NCHHSTP), Centers for Disease
Control and Prevention (CDC). This material is in
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for other publications, information, and
 
resources available from DTBE.
 
Charles’ departure from his position not only is a 
loss for the State of Texas: it also leaves a huge 
void at the national and international levels of TB 
control. Never one to shy away from additional 
responsibilities, he is the quintessential public 
health servant leader. Dr. Wallace served as the 
National TB Controllers Association (NTCA) 
Board President in 2001 and 2011. In 2007 and 
2008, he served as the Vice­President/ Program 
Chair for the North America Region of the 
International Union Against Tuberculosis and 
Lung Disease (IUATLD). During 2005 and 2006, 
he served as the Secretary Treasurer and Chair 
It is hard to find a man
who is so passionate
and committed to his work.
of the Abstract 
Committee. 
Menn Biagtan, MD, 
MPH, Program 
Manager, British 
Columbia Lung Association, shared the following 
thoughts about Dr. Wallace: “It is hard to find a 
man who is so passionate and committed to his 
work. He takes every task seriously, and yet he’s 
got a good sense of humour. He is well loved and 
respected by his colleagues at the NAR Region. I 
was just so fortunate to have worked with him.” 
In addition, Dr. Wallace was a member of the 
Advisory Committee for the Elimination of 
Tuberculosis (ACET) from July 2000 to June 
2002, and he was the ACET Liaison 
Representative, representing NTCA from June 
2011 to June 2012. 
Many of us remember the National TB 
Conference in Atlanta immediately following 
Hurricane Katrina, when Charles Wallace and 
Charles DeGraw (director of the Louisiana TB 
Control Program) were overwhelmed with 
emotion describing the efforts and successes of 
their respective TB control programs in locating 
and resuming critical TB treatment to those who 
had fled the state in the immediate aftermath of 
the hurricane. It is with that same emotion and 
personal commitment that Charles did his job, 
day in and day out, in the aftermath of an 
unprecedented crisis or in the routine work and 







of the NTCA, has this tribute to Dr. Wallace’s 
legacy in TB control: “My friend Charles has been 
a constant inspiration to me ever since I became 
involved in TB control and prevention at the state 
level many years ago. Through his involvement 
in NTCA and in the TBESC, the self­effacing yet 
powerful words of Charles Wallace have 
challenged the status quo, whether that be public 
health practices or research priorities, always 
pointing to those we serve and to the ethical 
challenge of eliminating health disparities across 
all boundaries.” 
My friend Charles has been a
constant inspiration to me ever
since I became involved in TB
control and prevention at the state
level many years ago.
6
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Charles is someone I admire
and respect. He is a true






and now Executive Director of Stop TB USA, 
says of Dr. Wallace, “Charles is someone I 
admire and respect. He is a true public health 
hero in my eyes. Charles has loved his ’TB 
journey’ in spite of the many obstacles that he 
has faced along the way, obstacles that others 
may have found difficult to overcome. He 
embodies the sentiment that you do not give up 
when you still have something to give. His 
leadership and untiring advocacy for public 
health and the disenfranchised persons of the 
world are remarkable. Even more importantly, his 
gentle manner, enthusiasm, warmth, and humor 
are truly inspirational to all who have been 
fortunate enough to be his friend and colleague.” 
TB control and prevention, for Dr. Charles 
Wallace, is not an occupation but a passion, a 
mission, and a commitment to others and their 
health — this has been evident in everything he 
undertakes. We hope that, in his retirement, 
Charles will return in some capacity to rejoin the 
fight against TB. In the meantime, as friends and 
colleagues, we celebrate the many 
accomplishments of Dr. Wallace, and will carry 
on his legacy of inspiration, compassion, and 
justice. 
—Reported by Donna Wegener
Executive Director
National TB Controllers Association




The following is reprinted with permission from
The Snohomish Times.
The Snohomish Health District Tuberculosis (TB) 
Program was presented with the “2013 
Outstanding TB Team” award from the 
Washington State Department of Health TB 
Program on October 23, 2013, at the annual 
conference of state and local public health TB 
specialists in Tacoma. 
State officials said the Snohomish Health District 
TB Program received the honor because of the 
staff’s dedication to and leadership in TB control 
in Washington. The Health District’s TB team 
handles some of the highest rates and most 
complicated cases of TB in the state. 
“Tuberculosis is a serious disease that can be 
fatal, yet it is curable and preventable, so the 
community work of local health staff like those in 
Snohomish County is vital to prevention,” said 
Secretary of Health John Wiesman. “The 
knowledge and expertise of the Snohomish 
Health District TB Program staff, along with their 
outstanding performance and dedication to TB 
control, is clearly helping make the community 
they serve safer and healthier there and 
throughout the state.” 
The TB program recently completed the 
treatment and management of four connected 
cases of active TB begun in 2012 among mental 
health patients in Everett. In addition to finding 
the active cases, the TB team looked for people 
who had been exposed over time to the lung 
disease. This led to screening and testing 107 
more people for TB. Of those, 11 were treated for 
latent TB infection, which means they have 
breathed in TB bacteria but are not actively sick. 
7
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The local TB program in Snohomish County 
handles 20 to 26 active cases of TB annually. In 
prior years, staff worked on a complex medical 
investigation in the drug­using community, in a 
local high school, and in multicultural 
communities. An additional challenge is the rising 
incidence of TB that is resistant to many 
antibiotics used for treatment. 
“All of us at the Snohomish Health District are 
very proud of our TB program staff for their 
devotion to helping people who have TB or who 
could get sick from it,” said Dr. Gary Goldbaum, 
Health Officer and Director of the county’s public 
health agency. “They do excellent, difficult work 
every day to keep county residents healthy. The 
‘Outstanding TB Team’ award from the State 
Department of Health is an exciting and valued 
recognition of their effort.” 
The program team members were Dr. Chris 
Spitters, physician consultant; Dr. Joseph 
Aharchi, program manager; nurses Naomi Kern, 
Karen Winchell, Anna Hippchen, and Christina 
Griffiths; Alicia McQuen, disease investigation 
specialist; outreach workers and linguists Vanny 
Khy­Preston and Kon Setiaev; and support staff 
Lisa Pederson, Sally Anderson, and Linda 
Douglas. 
—Reported by The Snohomish Times
Snohomish, WA




On October 24, 2013, Dr. Sundari Mase, Medical 
Officer with DTBE’s Field Services and 
Evaluation Branch, gave a Brown Bag 
presentation on the new TB drug, bedaquiline 
(BDQ). The following is a summary of her talk. 
What is BDQ? It’s a diarylquinoline, i.e., it’s in the 
fluoroquinolone class of drugs. It’s intended to be 
used as part of combination therapy in adults (≥ 
18 years) with pulmonary multidrug­resistant 
(MDR) TB. This is the first new type of drug in 40 
years to obtain approval from the Food and Drug 
Administration (FDA) for treating TB. It works 
through an unusual mechanism: it inhibits a 
process (the ATP synthase proton pump) that 
creates energy for the bacterium. BDQ is 
manufactured by Janssen, a subsidiary of 
Johnson & Johnson, and sold under the trade 
name Sirturo. BDQ is available from one 
distributor, Metro Medical Supply, which is in 
Tennessee. During the initial roll­out, Janssen 
will oversee the process of BDQ distribution to 
the 68 CDC­funded jurisdictions. 
BDQ was approved under the FDA’s accelerated 
approval program, which allows FDA to approve 
a drug that treats a serious disease, based on 
clinical data showing that 
•	 The drug has an effect on a surrogate 
endpoint, time to sputum culture conversion 
from positive results for M. tuberculosis to 
negative results, that is reasonably likely to 
predict a clinical benefit to patients with a 
serious or life­threatening illness 
•	 It provides meaningful therapeutic benefit to 
patients over existing treatments. 
Effectiveness: When tested in the laboratory, at 
recommended levels, BDQ is potent against both 
active and inactive M. tuberculosis. And when 
tested in mice, BDQ has significant bactericidal 
and sterilizing activity. However, at lower levels 
(0.3 mcg/ml), bedaquiline has a bacteriostatic 
effect and acquired resistance is more likely. (A 
bacteriostatic agent is an agent that stops 
bacteria from reproducing, while not necessarily 
harming them otherwise. Upon its removal, the 
bacteria usually start to grow again. This is in 
contrast to bactericidal agents, which kill 
bacteria.) 
Dosage: The recommended dose of BDQ for the 
treatment of pulmonary MDR TB in adults is 400 
mg given orally once daily for 2 weeks, followed 
by 200 mg orally three times weekly, for a total 
treatment duration of 24 weeks. It is to be taken 
8
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with food and in combination with other anti­TB 
drugs. The drug is available in 100 mg tablets. 
Cost: This is a major consideration. A 24­week 
regimen costs 
•	 $30,000 for privately insured individual 
patients 
•	 $23,070 through the VA 340B plan for public 
health departments and other governmental 
entities 
Procurement process: So far, most jurisdictions 
do not have a contract for Medicaid patients to 
get coverage for BDQ. Private insurance 
payment decisions will be made on a case­by­
case basis. The good news is that patient 
assistance will be available for uninsured patients 
through the J&J foundation. Insured patients will 
have the option of a co­pay adjustment program. 
Limitations: The FDA label states that neither the 
safety nor efficacy of BDQ has been established 
for the treatment of extrapulmonary TB, latent TB 
infection (LTBI), or drug­susceptible TB. 
However, the CDC guidelines give 
recommendations for off­label use of BDQ for 
extrapulmonary TB. The CDC guidelines do not 
mention its use for LTBI or drug­susceptible TB. 
Warnings: For safety, you should reserve BDQ 
for when you cannot otherwise provide an 
effective treatment regimen for a patient with 
MDR TB. BDQ’s safety risks require careful 
patient selection and active monitoring. It should 
be administered by directly observed therapy 
(DOT). Specific concerns are as follows: 
Increased risk of death. In one placebo­
controlled trial, there were increased deaths 
in the BDQ treatment group (9/79, 11.4%) 
compared to the placebo treatment group 
(2/81, 2.5%). 
There was a significant imbalance in deaths, 
with more in the BDQ group. TB was the 
cause of death in 2/2 placebo deaths and in 
5/10 BDQ deaths, which were all after BDQ 
treatment had ended. Of the 10 deaths in the 
BDQ group, 8 patients had a conversion of 
sputum culture results from positive for M. 
tuberculosis to negative (i.e., had culture 
conversion). No pattern was observed 
between death and culture conversion, 
relapse, microbiologic response, 
susceptibility to background regimen (i.e., 
standard four­ or five­drug therapy, to which 
BDQ is added), HIV infection, and severity of 
disease. The reason for imbalance in deaths 
is unknown. 
Cardiac events: The drug can cause an 
irregular heart rhythm owing to QT interval 
prolongation. In cardiology, the QT interval is 
a measure of the time between the start of 
one wave (the Q wave) and the end of the 
following wave (the T wave) in the heart's 
electrical cycle. A lengthened QT interval is a 
biomarker for ventricular heart rhythm 
disorders and a risk factor for sudden death. 
And using BDQ with other drugs that prolong 
the QT interval (such as some drugs for HIV 
infection) may cause additive QT 
prolongation. This could be life­threatening. 
Liver damage: BDQ can be toxic to the liver. 
Concurrent conditions and medications 
associated with liver toxicity could pose 
additive hazards. Make the following 
adjustments in patients with kidney or liver 
impairment: 
•	 Mild or moderate kidney or liver 
impairment — no dosage adjustment 
needed 
•	 Severe kidney impairment — use with 
caution 
•	 Severe liver impairment ­­ do not use 
Lingering effects: BDQ has a long half­life. It 
remains in the body for months after the drug 
is stopped. Consider discontinuing BDQ 4–5 
months before stopping the other drugs in 
the regimen, to reduce or avoid an extended 
9
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period of exposure to low levels of BDQ in 
the absence of other medications which are 
likely to be active against the infecting M. 
tuberculosis isolate. In addition, the QT 
interval (see above) takes a few months to 
revert to baseline. 
Concerning but indefinite conclusions: A 
greater number of deaths among patients 
who took BDQ in the treatment trials. The 
reason for the imbalance could not be 
determined from the current safety data. Half 
the deaths were attributed to worsening of 
the underlying condition. 
The role of BDQ in deaths where liver toxicity 
and heart failure are contributors could not 
be excluded. An association between BDQ 
and these deaths is difficult to determine 
because of the underlying condition, other 
co­existent medical conditions, and other 
drugs being given concurrently (background 
regimen). 
What else do TB programs and clinicians need to 
know? You will need to monitor patient’s 
progress as follows: 
•	 Symptoms. Monitor patient weekly for 
nausea, headache, hemoptysis, chest pain, 
arthralgia (joint pain), and rash. 
•	 Drug side effects. Monitor patient for other 
side effects related to other drugs in regimen. 
Note: Do not use BDQ with rifamycins, or 
other drugs that induce or suppress 
CYP3A4. 
•	 Culture. Send one sputum specimen monthly 
to a TB laboratory for culture. 
CDC also asks that you participate in monitoring 
for resistance. With the help of your public health 
laboratory, send one pre­treatment isolate and 
one additional isolate per month to CDC for 
surveillance of BDQ resistance. 
Distribution. Janssen is providing oversight of 
BDQ distribution. A point of contact (POC) has 
been selected for each of the 68 CDC­funded 
jurisdictions. These persons will (1) ensure that 
the patient meets criteria for BDQ, (2) facilitate 
procurement of BDQ, (3) work with the clinician, 
nurse, and case manager, and (4) ensure that 
expert consultation is sought. So far, the process 
has been smooth. 
In summary, how could BDQ help? It could 
provide 
•	 A stronger regimen for cases with extensive 
resistance or drug intolerance. 
•	 A shorter regimen. 
•	 A regimen less toxic than current MDR TB 
regimens. 
Importantly, how could it hurt? 
•	 Could cause liver toxicity and death. 
•	 Prevents use of other drugs, i.e., 
moxifloxacin (MFX), clofazimine; most pre­
XDR or XDR cases are treated with MFX. 
•	 Could be misused, or used in a weak 
regimen leading to drug resistance. 
•	 Can be costly and complex to procure. 
TB program directors can call their DTBE 
Program Consultant for further information, such 
as the name of the POC for their jurisdiction. 
—Reported by Sundari Mase, MD,
and Ann Lanner
Div of TB Elimination
NTCA Responds to the
 




TB drugs and diagnostics are truly a lifeline for 
TB control. However, shortages and price 
increases periodically make these tools 
inaccessible to health care providers. A series of 
shortages and price increases in TB drugs and 
diagnostics started in the fall of 2012 and 
continued in 2013. To address these problems 
nationally, federal agencies and advocacy 
organizations need real­time, verifiable 
10
 
   
 
 
               
  
 
               
             
               
             
               
               
         
       
           
         
             
             
           
               
     
 
             
               
             
                 
             
         
             
            
 
             
           
                 
               
               
             
         
         
               
               
           
                 
         
             
  
 
             
  
            
             
         
            
           
   
          
           
         
            
         
         
            
   
          
           




          
           
           
     
 
            
            
 
            
        
              
       
          
         
   
 
           
           
             
       
           
         





information about the scope and effects of these 
shortages. 
The NTCA has been engaged in discussions with 
directors of TB control programs about the 
impact of these shortages on programs and on 
the patients served. For example, state program 
staff have been diverted from TB control activities 
to respond to frequent inquiries from local health 
departments and other community providers 
(hospitals, schools, correctional facilities, 
pharmacies, and long­term care facilities) about 
the shortages of tuberculin purified­protein 
derivative antigen solutions and how to meet 
state rules for testing. Program directors and 
healthcare providers have made decisions about 
setting priorities for whom to test, and ultimately 
to treat. 
The TB community needs firm, clear information 
to provide to federal agencies to document the 
shortages and the price increases; however, to 
date there has been no single place to report 
these issues. In response, the NTCA Drug 
Shortages Workgroup developed an online 
system to report shortages of, and price 
increases in, TB drugs and diagnostics. 
The TB Drugs and Diagnostics Reporting Form 
was developed and pilot­tested by NTCA 
members. It is intended for use by personnel in 
state, regional, county, and city TB programs as 
well as in public and private sector organizations 
that include TB screenings in their health 
maintenance activities, such as universities, 
schools, correctional facilities, hospitals, and 
long­term care facilities, to report a shortage or 
price increase of a TB drug or diagnostic. 
Interferon gamma release assays (IGRAs) were 
added prior to release of the reporting form, in 
recognition that some areas experienced 
interruptions in supply during the TB biologics 
shortage. 
Goals for this reporting and tracking system 
include­
•	 Provide an interim notification system for 
drug and diagnostic supply issues until a 
national system is in place. 
•	 Collect information on challenges in the 
United States relating to accessing drugs 
and diagnostics. 
•	 Describe the frequency and distribution 
of shortages and cost escalations over 
time in the United States. 
•	 Describe the effects of shortages on 
patients, programs, and TB control 
efforts in the United States. 
•	 Describe the actions taken to resolve 
access problems. 
•	 Provide summary data in periodic 
intervals to NTCA, CDC, FDA, policy 
makers, advocacy groups, and 
manufacturers working towards 
continuous, affordable pharmaceutical 
and diagnostic supplies. 
•	 Provide documented evidence of price 
escalations to the proper federal agency 
for a federal investigation into the 
reported cost increases. 
Attributes of the reporting mechanism include­
•	 Feasibility; simple, easy to use, brief, 
accessible 
•	 Relevance to users in different settings 
•	 Provision of actionable data 
•	 Ability to provide periodic reports and to 
be maintained by NTCA 
•	 Provision of definitions, terms, and 
categories that can accurately capture 
intended information 
The web­based reporting mechanism is available 
on the NTCA website’s home page, 
www.tbcontrollers.org. In addition to the link to 
the reporting mechanism, supplemental 
documents outline the background for the 
development of the reporting mechanism, 
instructions for the use of the reporting 
mechanism, and FAQs. 
11
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Please use this new tool to report the shortages 
and price escalations you have experienced. We 
ask that you also inform your community partners 
about this new reporting mechanism, so the 
database will have input from public and private 
health providers. 
NTCA will report to TB Notes periodically on the 
status of the reporting mechanism, the 
information submitted to our federal partners, and 
the effectiveness of documenting these issues. 
—Submitted by Jennifer Kanouse
and Donna Hope Wegener, on behalf of
the NTCA TB Drug Shortages Workgroup
TB EDUCATION AND TRAINING
NETWORK UPDATES
2014 TB ETN Conference
The thirteenth TB Education and Training 
Network (TB ETN) Conference will be held 
September 16–18, 2014, in Atlanta, Georgia. The 
location for the conference is CDC’s Roybal 
Campus. For a fourth year, TB ETN will join 
forces with the TB Program Evaluation Network 
(TB PEN) to deliver 2­and­a­half days of exciting, 
innovative, and rewarding plenary and breakout 
sessions. Planning is currently underway by TB 
ETN and TB PEN conference planning 
committees. Please visit our website in March 
2014 for additional details: 
www.cdc.gov/tb/education/tbetn/conference.htm 
—Reported by Peri Hopkins, MPH





4th Semiannual Meeting of the
Tuberculosis Epidemiologic Studies
Consortium-II
Approximately 60 principal investigators, project 
coordinators, and other consortium personnel 
attended the 4th Semiannual Tuberculosis 
Epidemiologic Studies Consortium­II (TBESC­II) 
Meeting on September 12, 2013, at the Crowne 
Plaza Ravinia Hotel in Atlanta, GA. After a warm 
welcome by Dr. Phil LoBue, DTBE’s Acting 
Director, Dr. Denise Garrett presented the 
preliminary results of the Consortium’s main 
study, Task Order (TO) 1: Prospective 
Comparison of the Tuberculin Skin Test and 
Interferon­Gamma Release Assays in 
Diagnosing Infection with Mycobacterium 
tuberculosis and in Predicting Progression to 
Tuberculosis. Then, during a session moderated 
by Dr. Tom Navin, meeting participants 
discussed the input from TBESC­II’s Board of 
Advisors and the future directions for the 
Consortium. This discussion reflected the 
recognition that some adjustments need to be 
made, including potential changes in TO1 
endpoints, intervention studies for improving 
latent TB infection (LTBI) diagnosis, and other 
next steps, including the creation of a “Protocol 
Revision Team.” 
Other highlights from the meeting included 
updates from the Cost­effectiveness Working 
Group by Dr. Lisa Pascopella and from the 
Biobanking Working Group by Dr. Bob Belknap. 
There was also discussion on the Registry Match 
and repeat testing of IGRAs. Planning for the 
next TBESC meeting, which will be held in July 
2014, is underway. 
—Reported by Denise Garrett, MD













DTBE’s Communications, Education, and 
Behavioral Studies Branch is excited to 
12
 
   
 
 
             
             
             
               
             
               
               
           
             
     
 
               
               
             
   
 
       
            
        
 
        
 
          
          
 
          
       
   
              
           
   
 
       
 
       
    
 




           
             
                 
           
         
           
             
         
        
        
          
       
        
 
               
         
           
            
 
   
         
          
 
       
         
                
         
       
     
 
                 
           
             
           
           
           
               
               
      
 
             
           
           
           
               
           





announce the release of the mobile application 
for health care providers, Latent TB Infection 
(LTBI): Guide for Diagnosis and Treatment. The 
mobile application was designed to make it easy 
to view CDC’s latest LTBI recommendations on 
an iPad, iPhone, iPod Touch, or Android device. 
When your device is connected to wireless or 
cellular service, the content is updated 
automatically to ensure you always have the 
most up­to­date information. 
This application serves as a ready and useful 
reference that highlights the main points of key 
guidelines for diagnosis and treatment of latent 
TB infection. 
Check out these features: 
•	 CDC guidelines on latent TB infection 
•	 Treatment table outlining regimen 
options 




•	 TB education and training resources 
•	 Sample documentation forms for TB 
testing 
•	 Ability to personalize your experience 
with highlighting, annotation, and 
bookmark options 
•	 Ability to share the content with others 
through social media, such as Facebook 
and Twitter 
Download the app today! 
—Reported by Maria Fraire Sessions, MPH, CHES
Div of TB Elimination
TB Contact Investigation Interviewing
Skills Course
Background 
The TB Contact Investigation Interviewing Skills 
Course is an interactive training course designed 
to improve the interviewing skills of both new and 
experienced staff responsible for conducting TB 
contact investigation interviews. The course 
development was a collaborative effort between 
DTBE and the following TB Regional Training 
and Medical Consultation Centers (RTMCCs): 
•	 Curry International Tuberculosis Center 
•	 Heartland National Tuberculosis Center 
•	 New Jersey Medical School Global 
Tuberculosis Institute at Rutgers 
•	 Southeastern National Tuberculosis Center 
The course provides an overview of the contact 
investigation process, basic communication and 
interviewing skills, and opportunities to apply 
those skills in role play activities. 
Target Audience 
Health care professionals responsible for 
conducting TB contact investigation interviews. 
Development of the Course 
A multi­phased, systematic health education 
process was utilized to develop the course. The 
five­step process includes needs assessment, 
development, pilot­testing, implementation, and 
assessing effectiveness. 
The need for this training was confirmed after a 
review of National Tuberculosis Indicators Project 
data showed poor performance in finding and 
evaluating TB contacts in some jurisdictions. 
Additionally, discussions with staff from DTBE’s 
Field Services and Evaluation Branch determined 
that there was a need for extensive interviewing 
skills training for public health staff who conduct 
TB contact investigations. 
Recognizing the need for an in­person intensive 
skill­building course, a 4­day curriculum was 
developed. Materials were adapted from DTBE, 
RTMCC, and STD interviewing courses. Pilot 
testing of the course took place from October 
2011 through December 2012. Eighteen pilot­test 
courses were conducted, resulting in a total of 
271 trained participants. 
13
 
   
 
 
               
               










               
             
           
           
           
         
           
           
           
             
         
 
 
           
           
             
           
                 
                   
             
               
             
           
                 
    
 
             
             
               
              
 
     
                 
             
               
             
              
 
               
                 
             
  
 
             
             
           
              
 
     
    
    
 
      
   
 
                     
             
             
               
               
           
           
           
                 
               
                 
     
 
               
               
               
             
             
               
               
             
             
           





Each RTMCC worked with CDC and selected TB 
programs in their respective regions to pilot test 






• Baltimore, MD 
• Florida 
• Washington 
Local TB program staff served as faculty, along 
with CDC public health advisors (PHAs) and 
program consultants. PHAs who served as 
course faculty included Shanica Alexander, Kim 
Do, Patrick Ndibe, Shameer Poonja, Sue 
Spieldenner, Vincent Fears, Cindy Castaneda, 
Edwin Rodriguez, Angel Roca, Vernard Green, 
Carlos Alcantara, Mark Miner, Tracina Cropper, 
Dawn Tuckey, Dan Dohony, Margaret Patterson, 
Vernell Fields, Scott Jones, Alan Locke, Kim 
Seechuck, Bruce Heath, and Maureen O’Rourke­
Futey. 
Feedback comments from the pilot course 
evaluations were very positive. For example, 
99% of participants either agreed or strongly 
agreed that their interviewing skills were 
enhanced as a result of the training. Many also 
stated that the training should be offered to all TB 
staff, and approximately 98% of participants said 
that they would recommend this course to others. 
Participants also stated that hearing about the 
contact investigation experiences from the PHAs 
and other course faculty was a valuable part of 
the course. 
Feedback from the course evaluations was used 
to make improvements to the course materials. 
After the final revisions were made, the course 
materials were uploaded to the DTBE website. 
Accessing the Training 
All of the RTMCCs now offer the TB Contact 
Investigation Interviewing Skills Course as part of 
their standard curriculum. If you are interested in 
participating in one of these trainings, please 
contact the RTMCC that serves your region. 
TB programs may also use the course materials 
to conduct their own trainings. All of the course 
materials are available on the DTBE website: 
www.cdc.gov/tb/education/skillscourse/default.htm. 
Instructions on how conduct this training are 
provided in the course Facilitator Guide. TB 
programs can also request technical assistance 
from their RTMCC to conduct the course. 
—Reported by Sarah Segerlind, MPH,
and Peri Hopkins, MPH
Div of TB Elimination




As many of you know, for the past 11 years the 
Atlanta Botanical Garden has been holding an 
annual event and competition, Scarecrows in the 
Garden. This year was no different, and neither 
was the participation of Dr. Wanda Walton and 
her branch, the Communications, Education, and 
Behavioral Studies Branch (CEBSB) of the 
Division of Tuberculosis Elimination (DTBE). This 
group likes to think of different and creative ways 
to educate others about tuberculosis (TB) – even 
if it means building a scarecrow! And not just 
your run­of­the­mill scarecrow… 
Last year they designed and built Miss Scare­let 
Crow’Hara, a stunning 6­foot crow in a lovely 
green dress. Scare­let invoked the image of the 
famous Gone with the Wind character Scarlet 
O’Hara, portrayed by the actress Vivian Leigh, 
who died of TB in 1967. Through various 
elements of the display, CEBSB staff provided a 
message about TB. Members of CEBSB who 
visited Scare­let in the Garden observed visitors 
stopping to admire Scare­let, and actually 
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The Atlanta Journal­Constitution included Scare­
let in their article about Scarecrows in the 
Garden, and noted that she was out and about 
with an important public service announcement. 
Buoyed by the fact that Scare­let was such a 
good spokes­bird, CEBSB decided to repeat their 
efforts. 
The creature that 
CEBSB came up 
with for this year 
was ... Edgar Allan 
Crow. And this 
Edgar was a­ravin’ 
against TB. Edgar’s 
name was the 







1849), and his 
family were haunted 
by tuberculosis. In 1810, when he was a young 
child, his mother died from TB. Later in life, his 
beloved wife Virginia, his brother Henry, and his 
stepparents also died of TB. 
Following these many losses, Poe published his 
poem “The Raven” in 1945. Some critics believed 
that the lost “Lenore” in the poem was inspired by 
events in Poe's own life, either to the early loss of 
his mother, Eliza Poe, or the long illness from TB 
endured by his wife, Virginia. It is not clear 
whether Poe had TB. His death has been 
attributed to alcohol, brain congestion, cholera, 
drugs, heart disease, rabies, suicide, 
tuberculosis, and other agents. 
Similar to Poe, Mr. Edgar Allan Crow has the 
artistic genius for writing “poe­try.” Mr. Crow and 
Ann Lanner, Public Health Analyst, co­wrote his 
first (and only) poem, with critical assistance from 
Joan Mangan, PhD, Behavioral Scientist, and 
Cheryl Tryon, Health Education Specialist. It is 
loosely based on “The Raven” and includes TB 
messages. 
A­Ravin’ Against TB! 
by Edgar Allan Crow 
Once upon an autumn dreary
 
As I pondered, none too cheery,
 
Late one night these words I heard
 
Coming from a learnéd bird­­

Spoken by a raven or a crow,
 
I can’t be sure.
 
Speaking with a bold presumption
 
Of this old disease Consumption,
 
“We must fight this airborne menace
 




‘Til we beat this ancient foe!”
 
Let’s fight TB together
 
‘Til TB is nevermore!
 
Quoth the crow … “TB Nevermore!”
 
Over the course of 10 weeks and many, many 
hours, CEBSB staff met—offsite and outside of 
regular work hours—to carry out an assortment 
of tasks under the tutelage of Joan Mangan and 
Cheryl Tryon. All expenses for this activity were 
shared by the CEBSB staff (entry fee, paint, and 
other supplies). 
Prior to being transported to the Atlanta Botanical
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Building 12 of Corporate Square. The reception 
in his honor featured a cake that was too pretty to 
eat, but was eaten all the same: a huge sheet 
cake decorated to look like a garden, with 
miniature hand­crafted fruits, vegetables, and a 
mini­Edgar Allan Crow. Maria Fraire Sessions, 
Team Lead of the Communications Team of 
CEBSB, orchestrated this segment of the project. 
This year’s crow building could not have been 
completed without the help of CEBSB family and 
friends! Joan Mangan’s house was the 
headquarters where this year’s scarecrow grew 
up. Joan and her mother, Joanrose Mangan, 
organized the team’s potluck dinners. Wanda’s 
partner, Martha Martin, led clean­up efforts after 
each dinner so the team could get right to work. 
Maria’s husband, David, cut up wood and boxes 
to allow safe transport of the garden cake. And 
Joan’s neighbors lent needed tools and 
enthusiastic support to cheer on the branch 
during the process. 
On October 3, Wanda and her team were among 
the crowd gathered at the Atlanta Botanical 
Garden to see the opening of the Scarecrows 
exhibit and to learn the winners of the contest. 
Please forgive the crowing, but out of 131 
scarecrows entered into this year’s competition, 
Edgar Allan Crow won first place in the non­
professional entry category. The group earned a 
framed certificate, and bragging rights for the 
coming year! 
All the scarecrows entered in the competition 
were on display at the Garden for the entire 
month of October. We hope CDC staff in Atlanta 
had a chance to come out to the Atlanta 
Botanical Garden and visit Edgar, the scariest TB 
educational product CEBSB has developed! 
Photo: DTBE’s Communications, Education, and 
Behavioral Science Branch. From left to right: (back 
row) Teresa Goss, Amera Khan, Peri Hopkins, Cheryl 
Tryon, Edgar Allan Crow, Sarah Segerlind, Maria 
Fraire Sessions. (Bottom row) Allison Maiuri, Molly 
Dowling, Wanda Walton, Joan Mangan, Ann Lanner. 
(Not pictured: Nicole Richardson­Smith.) 
—Submitted by Ann Lanner, Joan Mangan, Cheryl
Tryon, and Wanda Walton







A High-Tech Approach to
an Age-Old Problem
A new, cutting­edge diagnostic tool that helps 
detect TB in hours instead of days or weeks is 
being studied at 13 sites in Botswana, in hopes 
of improving TB detection time and getting more 
people treated faster. 
TB remains the leading killer of people living with 
HIV (PLHIV). In 2012, as many as 63 percent of 
TB patients in Botswana were co­infected with 
HIV. Additionally, Botswana faces a growing 
threat from multidrug­resistant (MDR) TB, a 
16
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disease that is much more difficult to diagnose 
and successfully treat. 
Until recently, health providers routinely relied on 
smear microscopy, a diagnostic tool developed 
more than 100 years ago, to detect TB in the 
sputum of patients. But this method can miss 
many TB cases — especially among PLHIV — 
and does not detect drug resistance. Other 
diagnostic methods can detect drug resistance, 
but it can take many weeks or months to receive 
results. 
It is hoped that a newly introduced diagnostic 
tool, called Xpert MTB/RIF, will help Botswana 
TB patients be treated as soon as possible 
through the rapid and accurate detection of TB 
disease and drug resistance. Thus, Xpert 
MTB/TIF may enable patients to be treated more 
quickly and, ultimately, save more lives. 
Xpert MTB/RIF is a molecular test that uses a 
DNA probe in a sealed test kit to detect TB in 
sputum with greater sensitivity than traditional 
tests, while also detecting resistance to 
rifampicin, one of the most effective first­line TB 
drugs, much more quickly. The test can be 
performed simply and safely by minimally trained 
staff, with results in approximately 2 hours as 
compared to the days or weeks that it took 
before. 
The U.S. government and the Botswana Ministry 
of Health have partnered to embark in an 
evaluation called XPRES (Xpert Package Rollout 
Evaluation Study) of the first 13 Xpert devices 
used in Botswana. The study’s objectives are to 
1) compare the sensitivity of the new Xpert 
diagnostic tool versus the older smear 
microscopy–based diagnostic tool when 
providing TB screening for PLHIV, and 2) 
evaluate the impact of Xpert on mortality rates of 
patients newly enrolled in antiretroviral therapy 
(ART). 
The study began in August 2012 and, to date, 
more than 4,300 participants have been enrolled. 
Machines have been placed in 12 districts 
covering 22 HIV care and treatment clinics that 
serve approximately 50 percent of PLHIV 
accessing ART. Lessons learned from the initial 
sites have informed the recent national 
expansion of the machines to an additional six 
sites — and plans for 14 more — across 
Botswana. 
Photo: clinic nurse preparing a sample for analysis 
using Gene Xpert at a point­of­care clinic, Botswana. 
Developing a successful new testing procedure 
in Botswana should help contain the spread of 
TB, which, in addition to saving lives here, could 
have an important public health benefit 
elsewhere in Africa and in the rest of the world. 
—Reported by Doug Johnson, MPH
Communications Officer, CDC Botswana






New Training Tool, “Essentials for
the Mycobacteriology Laboratory,"
Now On-Line!
The Association of Public Health Laboratories 
(APHL), in collaboration with CDC, is excited to 
present a new training tool, “Essentials for the 
Mycobacteriology Laboratory: Promoting Quality 
Practices.” This tool consists of a series of 
17
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interactive web­based modules for laboratorians, 
and is now online and publicly available. 
The modules are designed to enhance 
competency and to address those issues of 
common mycobacteriology laboratory practice 
affecting quality testing and safety of the 
laboratorian. There is no charge to access these 
trainings. 
There are currently four training modules 
available: 
•	 Overview of Tuberculosis 
•	 Laboratory Safety: Work Practices for 
Mycobacterium tuberculosis 
•	 Specimen Collection, Transport, Handling, 
and Processing 
•	 AFB Smear Microscopy 
In addition to the online modules, the website 
includes PDF versions of the content, as well as 
many additional resources to supplement each of 
the trainings. These tools can be utilized to suit 




access the modules. 
Collaborating with laboratory experts, including 
staff from CDC, APHL is continuing to develop 
new content for these training modules. 
Laboratories are encouraged to share the 
trainings within their networks with all who might 
benefit. The modules and other valuable TB 
resources can also be accessed through APHL’s 
homepage: 
http://www.aphl.org/Pages/default.aspx 
New Publications Addressing Use of
the Cepheid Xpert MTB/RIF Assay in
the United States
CDC Issues Guidance on the Xpert
MTB/RIF Assay
At the end of July 2013, the Food and Drug 
Administration (FDA) granted market 
authorization to the Cepheid Xpert MTB/RIF 
assay. This nucleic acid amplification (NAA) test 
can simultaneously identify Mycobacterium 
tuberculosis complex (MTBC) and detect genetic 
mutations associated with resistance to rifampin 
from raw sputum and concentrated sputum 
sediments. A major advantage of this test is that 
results are available in less than 2 hours. 
In October 2013, CDC published interim 
guidance in the Morbidity and Mortality Weekly 
Report (MMWR). The guidance describes the 
background of this NAA test, practical 
considerations for its use in clinical decision 
making, and considerations for its use in infection 
control. The MMWR article provides a table 
highlighting interpretation, as well as proposed 
minimum laboratory report language for results 
from the Xpert MTB/RIF assay. It also includes 
an analysis of results of sputum smear and NAA 
testing for infection control in health­care settings 
involving patients with suspected tuberculosis. 
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm 
6241a1.htm?s_cid=mm6241a1_w 
APHL Releases Xpert Fact Sheet for
Laboratorians
Recently, APHL’s TB Subcommittee published 
Laboratory Considerations for Use of Cepheid 
Xpert MTB/RIF Assay, which is intended to guide 
laboratories to integrate this assay into existing 
TB testing practices. The document emphasizes 
the use of the Xpert MTB/RIF assay as part of a 
comprehensive testing algorithm that includes 
acid­fast bacilli (AFB) smear and culture, as well 
as drug­susceptibility testing. Included within the 
document is a summary of the considerations 
each laboratory should make based on in­house 
testing capabilities. This document may be 
distributed to clinical laboratory partners and 
other laboratory stakeholders. It is important to 
emphasize that the Xpert MTB/RIF assay does 
18
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Please contact APHL at info@aphl.org for more 
information. 
—Reported by Frances Tyrrell, MPH, MT (ASCP), SM
Div of TB Elimination
NEW CDC PUBLICATIONS
Auld SC, Click ES, Heilig CM, Miramontes R, 
Cain KP, Bisson GP, Mac Kenzie WR. 
Association between tuberculin skin test result 
and clinical presentation of tuberculosis disease. 
BMC Infect Dis. 2013 Oct 4;13:460. doi: 
10.1186/1471­2334­13­460. 
Auld SC, Click ES, Heilig CM, Miramontes R, 
Cain KP, Bisson GP, Mac Kenzie WR. Tuberculin 
skin test result and risk of death among persons 
with active TB. PLoS One 2013 Nov 11; 
8(11):e78779. doi: 0.1371/journal.pone.0078779. 
Bristow CC, Podewils LJ, Bronner LE, Bantubani 
N, Walt Mv, Peters A, Mametja D. BMC Public 
Health. TB tracer teams in South Africa: 
knowledge, practices and challenges of tracing 
TB patients to improve adherence. 2013 Sep 
4;13:801. doi: 10.1186/1471­2458­13­801. 
Coleman MS, Marienau KJ, Marano N, Marks 
SM, Cetron MS. Economics of United States 
tuberculosis airline contact investigation policies: 
A return on investment analysis. Travel Med 
Infect Dis 2013 Nov 8. doi:pii: S1477­8939 
(13)00185­3. 10.1016/j.tmaid.2013.10.016. [Epub 
ahead of print.] 
Cruz AT, Starke JR, Lobato MN. Old and new 
approaches to diagnosing and treating latent 
tuberculosis in children in low­incidence 
countries. Curr Opin Pediatr. 2013 Dec 2. [Epub 
ahead of print.] 
Dorman SE, Belknap R, Graviss EA, Reves R, 
Schluger N, Weinfurter P, Wang Y, Cronin W, 
Hirsch­Moverman Y, Teeter LD, Parker M, 
Garrett DO, Daley CL; for the Tuberculosis 
Epidemiologic Studies Consortium. Interferon­γ 
release assays and tuberculin skin testing for 
diagnosis of latent tuberculosis infection in 
healthcare workers in the United States. Am J 
Respir Crit Care Med 2013 Dec 3. [Epub ahead 
of print.] 
Farhat MR, Shapiro BJ, Kieser KJ, Sultana R, 
Jacobson KR, Victor TC, Warren RM, Streicher 
EM, Calver A, Sloutsky A, Kaur D, Posey JE, 
Plikaytis B, Oggioni MR, Gardy JL, Johnston JC, 
Rodrigues M, Tang PK, Kato­Maeda M, 
Borowsky ML, Muddukrishna B, Kreiswirth BN, 
Kurepina N, Galagan J, Gagneux S, Birren B, 
Rubin EJ, Lander ES, Sabeti PC, Murray M. 
Genomic analysis identifies targets of convergent 
positive selection in drug­resistant 
Mycobacterium tuberculosis. Nat Genet 2013 
Oct;45(10):1183­9. doi: 10.1038/ng.2747. Epub 
2013 Sep 1. 
Floyd S, Sismanidis C, Yamada N, Daniel R, 
Lagahid J, Mecatti F, Vianzon R, Bloss E, 
Tiemersma E, Onozaki I, Glaziou P, Floyd K. 
Analysis of tuberculosis prevalence surveys: new 
guidance on best­practice methods. Emerging 
Themes in Epidemiology 2013 10:10; 
doi:10.1186/1742­7622­10­10. 
Gler MT, Guilatco R, Caoili JC, Ershova J, 
Cegielski P, Johnson JL. Weight gain and 
response to treatment for multidrug­resistant 
tuberculosis. Am J Trop Med Hyg 2013 Nov; 
89(5): 943­9. doi: 10.4269/ajtmh.13­0011. Epub 
2013 Sep 9. 
Mangan JM, Galindo­Gonzalez S, Irani TA. 
Development and initial testing of messages to 
encourage tuberculosis testing and treatment 
among bacille Calmette­Guerin (BCG) 
vaccinated persons. Journal of Immigrant and 
Minority Health 2013. Published online ahead of 
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print Oct. 20, 2013. DOI: 10.1007/s10903­013­
9928­z. 
Nandakumar S, Kannanganat S, Dobos KM, 
Lucas M, Spencer JS, Fang S, McDonald MA, 
Pohl J, Birkness K, Chamcha V, Ramirez MV, 
Plikaytis BB, Posey JE, Amara RR, Sable SB. O­
mannosylation of the Mycobacterium tuberculosis 
Adhesin Apa Is Crucial for T Cell Antigenicity 
during Infection but Is Expendable for Protection. 
PLoS Pathog 2013 Oct; 9(10): e1003705. doi: 
10.1371/journal.ppat.1003705. 
Shea KM, Kammerer JS, Winston CA, Navin TR, 
Horsburgh CR Jr. Estimated rate of reactivation 
of latent tuberculosis infection in the United 
States, overall and by population subgroup. Am J 
Epidemiol. 2013 Oct 18. [Epub ahead of print]. 
Shepardson D, Marks SM, Chesson H, Kerrigan 
A, Holland DP, Scott N, Tian X, Borisov AS, 
Shang N, Heilig CM, Sterling TR, Villarino ME, 
Mac Kenzie WR. Cost­effectiveness of a 12­dose 
regimen for treating latent tuberculous infection in 
the United States. Int J Tuberc Lung Dis. 2013 
Dec 1;17(12):1531­7. doi: 10.5588/ijtld.13.0423. 
Walter ND, Painter J, Parker M, Lowenthal P, 
Flood J, Fu Y, Asis R, Reves R; for the TB 
Epidemiologic Studies Consortium. Persistent 
latent tuberculosis reactivation risk in U.S. 
immigrants. Am J Respir Crit Care Med 2013 
Dec 5. [Epub ahead of print.] 
PERSONNEL NOTES
SEOIB has had several internal changes in 
staffing, both temporary and permanent, as 
follows: Lee Ann Ramsey has temporarily 
departed SEOIB to be the DTBE Acting 
Associate Director for Management and 
Operations (ADMO); Brian Sizemore has 
temporarily departed the Epidemiology Team to 
be SEOIB Acting Deputy Branch Chief; Anne 
Marie France has accepted the position of the 
Molecular Epidemiology Activity Lead; Sandy 
Althomsons returned to SEOIB after a 3­month 
mission in South Sudan with Doctors Without 
Borders and has joined the Outbreak 
Investigations Team; Tracie Gardner is the new 
NCHHSTP EIS Lead; and Lauren Lambert has 
joined the Molecular Epidemiology Activity. 
The DTBE Think Tank members are the worthy 
recipients of the DTBE Director’s Quarterly 
Recognition Award for the first quarter of 2014. 
Members of the Think Tank are Vernard Green, 
Chad Heilig, Christine Ho, Amera Khan, Bill 
MacKenzie, Brittany Moore, Krista Powell, Sarita 
Shah, and Angela Starks. 
In mid­2013, the DTBE Division Director charged 
the Think Tank with offering “creative, concrete 
recommendations for cross­cutting activities to 
carry out DTBE’s mission over the next 3­5 
years.” They were to make recommendations for 
1) maintaining or restructuring TB control in the 
United States, 2) defining DTBE’s activities and 
structure as they relate to global TB control, and 
3) addressing future DTBE staffing needs. 
The group immediately went to work, putting into 
place a series of rapid, substantive meetings, 
and using a comprehensive and highly analytic 
approach. Over a period of 6 weeks, Think Tank 
members went above and beyond their regular 
job duties and conducted intensive research, 
discussion, and writing of recommendations. This 
culminated in a 9­part, 26­page document that 
included recommendations on diverse aspects of 
the Division’s activities and strategy. The 
analysis and recommendations fed directly into a 
senior staff strategic budget planning process 
and now are being used by three groups 
planning out the organizational and functional 
future of DTBE in consideration of potential future 
budget reductions. 
The work of the Think Tank has been extremely 
well­received by Division leadership and Senior 
Staff. Think Tank members have provided unique 
input into the Division’s strategic planning 
process at a critical juncture. Their ability to rise 
20
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above parochial concerns and describe long­term 
objectives has provided a powerful impetus to the 
Division’s planning and decision making. 
Congratulations to the DTBE Think Tank for this 
well­deserved honor. 
Warren Benson will be retiring from CDC and 
federal service, effective December 30, 2013, 
after 43 years of service with the federal 
government. Warren started his federal career in 
1971 as a Data Analyst with the U.S. Navy and 
joined CDC in 1993 as an Office Automation 
Clerk with the Division of Reproductive Health. 
Warren has held several other positions at CDC 
including a stint within the Division of Adolescent 
and School Health as a Fiscal Accounting 
Assistant and finally moving to DTBE in 1999 as 
an Administrative Officer and Resource 
Management Specialist. There is a chance that 
you may unknowingly encounter Warren 
sometime in the future because Warren is a 
certified FAA Air Traffic Controller. He may 
decide to put those skills to use, but for now 
Warren is looking forward to traveling, fishing, 
catching up on reading, and spending time with 
his two dachshunds, Penny and Precious. 
RADM Kenneth G. Castro, MD, Assistant 
Surgeon General, USPHS, Commanding Flag 
Officer, CDC/ATSDR Commissioned Corps, has 
been selected to receive The International Union 
Against Tuberculosis and Lung Disease North 
American Region Lifetime Achievement Award. 
This is a great and well­deserved honor for Ken’s 
extraordinary contributions to the control, 
prevention, and eventual elimination of TB. Ken, 
who has served as the Director of the Division of 
Tuberculosis Elimination since 1993, has been 
on detail as Director of the Division of HIV/AIDS 
Prevention (DHAP), NCHHSTP, CDC, since 
August 2013. 
On Dec. 16, Dr. Castro announced his decision 
to vacate the position of Director, DTBE, effective 
December 31, 2013, and his plans to seek 
voluntary retirement from the Commissioned 
Corps near the end of FY 2014. The 
announcement for the recruitment of a new 
permanent Director will be made in early 2014. 
Under Dr. Castro’s leadership, we saw the 
reversal of the 1985­1992 resurgence of TB in 
the United States, and the steady downward 
incidence trends over the past 20 years, 
achieving the historic lowest incidence of this 
disease in the U.S. by 2012. DTBE staff 
produced guidelines to prevent the transmission 
of Mycobacterium tuberculosis complex in 
healthcare and other congregate settings. DTBE 
has provided supportive oversight of 62 
cooperative agreements (CoAgs) between CDC 
and states, territories, and several large cities to 
implement core program functions and 
continuously evaluate progress. DTBE has also 
provided programmatic innovation and leadership 
by initiating the gradual redirection of CoAg 
resources, starting in 2005, to better address 
burden of disease and complexity of case 
management, provide a much­needed safety net 
for persons afflicted with TB, and most recently 
introduced performance­based funding incentives 
as part of the CoAgs. DTBE staff provide, and 
ensure access to, subject matter expertise and 
human development capacity through the CDC­
funded TB Regional Training and Medical 
Consultation Centers. This has facilitated access 
to expert medical consultation and specialty 
training across the country. There is ongoing 
collaboration with DGMQ to revise and improve 
culture­based overseas TB screening and 
treatment of U.S.­bound immigrants and 
refugees. 
DTBE has supported the implementation and use 
of universal genotyping of M. tuberculosis strains 
from persons reported with TB, coupled with the 
continued provision of national emergency and 
outbreak response capacity, to investigate and 
better understand transmission dynamics and 
thus interrupt those transmission chains. DTBE 
has also supported the provision of national and 
supranational reference laboratory diagnostic 
services, along with the evaluation and 
implementation of advanced molecular methods 
21
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for the rapid detection of TB and of drug­resistant 
strains. This has revolutionized the ability to 
rapidly detect TB and drug resistance, instead of 
exclusively relying on solid culture media for a 
slow­growing pathogen. DTBE has developed 
and published updated evidence­based 
guidelines for the use of interferon gamma 
assays to detect latent TB infection. DTBE has 
also provided longstanding support of two highly 
productive epidemiologic and clinical research 
consortia, thus enabling the implementation of 
randomized clinical trials which demonstrated the 
efficacy of once­weekly rifapentine containing 
regimens in the continuation phase of therapy, 
the safety and efficacy of a 12­dose regimen for 
the treatment of persons with latent TB infection, 
and the need for extended use of isoniazid to 
prevent TB disease in people infected with HIV. 
DTBE has also recognized and documented 
recent unprecedented national shortages in anti­
TB drugs and diagnostic tests for latent TB 
infection. DTBE is now working with partners to 
seek solutions to these novel problems. And we 
can point to the fact that partners such as 
PEPFAR, USAID, WHO, Stop TB Partnership, 
the UNION, and host countries around the globe 
rely on our subject­matter expertise to advance 
our collective understanding of the epidemiologic 
drivers of TB and use that information to improve 
our interventions to advance global prevention 
and control. 
Dr. Castro has asked to be placed into a Senior 
Medical Officer position at the Center until the 
effective date of his Commissioned Corps 
retirement near the end of FY 2014, to enable the 
recruitment of a permanent Director, DTBE, who 
– in turn – can make selections for the various 
positions that are presently occupied on an 
interim/acting basis. 
Sekai Chideya, a Medical Officer for SEOIB’s 
Epidemiology team, has taken a temporary detail 
with the Mycotic Diseases Branch, Division of 
Foodborne, Waterborne, and Environmental 
Diseases, National Center for Emerging and 
Zoonotic Infectious Diseases. 
Gabrielle Fanning­Dowdell has joined SEOIB’s 
Epidemiology Team as a Project Coordinator. 
Gabby is a contractor with Northrop Grumman 
and will be working closely with TBESC partners 
to facilitate study enrolment, data management, 
and analysis. Welcome Gabby! 
Derrick D. Felix has transferred from Honolulu, 
Hawaii, to Atlanta, Georgia, and will continue 
working in the Field Services and Evaluation 
Branch of DTBE. In his new role, Derrick will be 
the Program Consultant for Alaska, Hawaii, and 
the U.S.­affiliated Pacific Islands (USAPI), which 
include, American Samoa, the Commonwealth of 
the Northern Mariana Islands, the Federated 
States of Micronesia, Guam, the Republic of the 
Marshall Islands, and the Republic of Palau. 
Derrick’s start date in Atlanta was Dec. 1, 2013. 
Prior to his reassignment to headquarters, 
Derrick served 8 years in Honolulu, Hawaii, as 
the Senior Public Health Advisor with the Hawaii 
TB Control Program. In that capacity, he 
managed the CDC TB cooperative agreement; 
developed and implemented programmatic 
activities to meet national TB objectives, which 
resulted in measureable improvements in state 
performance measures; established policies and 
procedures to standardize TB practices 
throughout the state; facilitated TB case 
conferences and cohort reviews; conducted 
quality assurance of TB surveillance data; served 
as lead for program evaluation; and provided 
various TB trainings statewide. Additionally, he 
provided technical assistance to local TB staff 
and partners throughout Hawaii and provided 
direct assistance with TB contact investigations 
in numerous dialysis centers, cruise ships, 
schools, and correctional facilities. He was also 
involved with regional TB control and prevention 
efforts, which included assisting with an Epi­Aid 
to the Republic of the Marshall Islands, providing 
monitoring and evaluation site visits to the 
Republic of the Marshall Islands and the 
Federated States of Micronesia at the request of 
the World Health Organization and Secretariat of 
the Pacific Community, and assisting with the 
22
 
   
 
 
             
      
 
               
                 
           
           
                 
               
             
   
 
           
             
           
                 
       
               
           
  
           
             
           
           
             
               
           
           
         
               
             
             
               
             
             
             
               
           
             
             
  
               
           
             
           
         
     
         
           
               
               
           
     
 
             
               
           
               
         
               
   
 
               
                 
           
           
               
             
               
               
             
                 
             
       
 
             
           
                 
         
             
             




             
             
             
               
             
               




coordination of the Pacific Island TB Controllers 
Association annual workshop. 
Derrick celebrated 10 years of service with CDC 
earlier this year and has spent that entire time 
with DTBE. His previous federal assignments 
include Fort Wayne, Indiana, and Chicago, 
Illinois. Prior to joining CDC, he worked one year 
as a Disease Intervention Specialist in the Palm 
Beach County TB Control Program in Delray 
Beach, Florida. 
Michael F. Iademarco, MD, MPH, Captain 
(USPHS), is leaving DTBE for another CDC 
leadership position. Beginning January 6, 2014, 
he will serve as Director of the Center for 
Surveillance, Epidemiology, and Laboratory 
Services (CSELS), which is part of CDC’s Office 
of Public Health Scientific Services (OPHSS). 
Michael’s expertise as a physician­scientist and 
laboratorian provide a strong foundation to lead 
CDC’s efforts to track America’s health, 
strengthen laboratory networks, and help public 
health officials identify the most urgent health 
threats. He most recently served as Chief of 
DTBE’s Laboratory Branch, where he oversaw 
clinical laboratory referral services and helped 
strengthen laboratory capacity building. From 
2006 to 2010, Michael was the Health and 
Human Services Health Attaché at the U.S. 
Mission in Vietnam, where he coordinated U.S. 
health activities for the Embassy and was the in­
country representative for the Office of the 
Secretary. In 2011, he was awarded a 
Government of Vietnam medal by the country’s 
prime minister in part for his work against 
HIV/AIDS. In addition, Michael served as 
Associate Director for Science for DTBE, where 
he oversaw the issuance of major guidelines. 
Michael is an adjunct faculty member of Emory 
University’s Division of Pulmonary, Allergy, and 
Critical Care Medicine. He serves as an 
attending physician annually at the Atlanta 
Veterans Administration Medical Center Medical 
Intensive Care Unit. 
Rose Punnoose has joined SEOIB’s 
Epidemiology Team as a Project Coordinator. 
Rose is a contractor with Northrop Grumman and 
will be working closely with TBESC partners to 
facilitate study enrolment, data management, and 
analysis. Welcome Rose! 
Chaturia Rouse has left the Epidemiology team 
of SEOIB for Medical School at Case Western 
University. Chaturia was a project coordinator 
with TBESC and worked closely with the data 
management system and site­specific enrolment. 
SEOIB wishes Chaturia all the best in her 
upcoming studies! 
Charlie Walker has joined CEBSB and will be 
working with DTBE as a web developer. He did 
his undergraduate studies and received a 
Master’s Degree in Technology Education from 
Jackson State University in Jackson, MS. Prior to 
coming to DTBE, Charlie worked for CDC’s 
OD/OCS, located at the Roybal campus; for the 
Department of Agriculture; and for IBM as a 
Web/SharePoint Analyst. Charlie is a member of 
the Omega Psi Phi Fraternity Inc. In his spare 
time, Charlie enjoys working out, playing flag 
football, and watching football. 
Liping Zhu, scientific data analyst contractor from 
Northrop Grumman and TBESC’s data manager, 
has left DTBE for a position with the National 
Center for Immunization and Respiratory 
Diseases. Liping led analysis on TBESC­I and 
TBESC­II study data. SEOIB wishes Liping all 
the best in her work with NCIRD! 
In Memoriam
Don Kopanoff passed away on December 17, 
2013, after a long illness resulting from 
Legionnaires disease. He had served as a long­
time and valuable CDC employee for 34 years. 
Don retired from the Division of Tuberculosis 
Elimination (DTBE) on April 1, 1994, after last 








                 
             
           
         
             
                   
               
           
    
 
                   
           
             
               
           
         
               
               
         
           
 
               
                   
             
             
     
 
   
 
       













































         





Don joined CDC in 1960 and first served in 
various field assignments with the Division of 
Sexually Transmitted Diseases and with the 
then­named Division of Tuberculosis Control 
(DTBC). He joined the headquarters staff of 
DTBC in 1967 as a member of the Training Unit, 
where he was instrumental in setting up several 
headquarters and field training courses, including 
TB Today. 
In the early 1970s, he played a major role in 
moving the TB Research and Development 
Branch from Bethesda, Maryland, to Atlanta, a 
very difficult task. From 1974 to 1990, Don 
served as Deputy Chief, Clinical Research 
Branch. Don received numerous awards, 
including one for his assistance in the early 
1990s in forming the National Coalition for the 
Elimination of Tuberculosis (NCET), the 
precursor to today’s Stop TB USA. 
After retiring, Don enjoyed spending his free time 
traveling the world with his wife, Alyce, as well as 
volunteering his time giving tours to school 
children at the Fernbank Museum of Natural 
History in Atlanta. 
CALENDAR OF EVENTS
February 27–March 1, 2014 
18th Annual UNION Conference ­ North 
American Region 
Boston, MA 
BC Lung Association 
March 3–6, 2014 








April 9–12, 2014 
Denver TB Course 
Denver, CO 
National Jewish Health 
April 28–May 2, 2014 
EIS Conference 
Atlanta, GA 
May 16–21, 2014 
American Thoracic Society (ATS) International 
Conference 
San Diego, CA 
American Thoracic Society 
June 1–4, 2014 
APHL Annual Meeting and 8th Government 
Environmental Laboratory Conference 
Little Rock, AR 
APHL 




June 10–13, 2014 
National TB Conference 
Atlanta, GA 
Grand Hyatt Atlanta in Buckhead 
For info, contact Donna Wegener, Eva Forest, or 
Sherry Brown. 
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